Protagenic Therapeutics (NASDAQ:PTIX – Get Free Report) is one of 954 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its rivals? We will compare Protagenic Therapeutics to similar businesses based on the strength of its profitability, institutional ownership, dividends, valuation, earnings, analyst recommendations and risk.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Protagenic Therapeutics and its rivals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Protagenic Therapeutics | 0 | 0 | 0 | 0 | N/A |
Protagenic Therapeutics Competitors | 6240 | 18205 | 42962 | 875 | 2.56 |
As a group, “Pharmaceutical preparations” companies have a potential upside of 80.86%. Given Protagenic Therapeutics’ rivals higher possible upside, analysts plainly believe Protagenic Therapeutics has less favorable growth aspects than its rivals.
Institutional & Insider Ownership
Earnings & Valuation
This table compares Protagenic Therapeutics and its rivals gross revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Protagenic Therapeutics | N/A | -$5.00 million | -1.17 |
Protagenic Therapeutics Competitors | $1.96 billion | $98.48 million | -4.64 |
Protagenic Therapeutics’ rivals have higher revenue and earnings than Protagenic Therapeutics. Protagenic Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Protagenic Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics’ rivals have a beta of 0.80, indicating that their average share price is 20% less volatile than the S&P 500.
Profitability
This table compares Protagenic Therapeutics and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Protagenic Therapeutics | N/A | -101.81% | -82.18% |
Protagenic Therapeutics Competitors | -2,641.23% | -227.21% | -30.33% |
Summary
Protagenic Therapeutics rivals beat Protagenic Therapeutics on 6 of the 10 factors compared.
Protagenic Therapeutics Company Profile
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.